Genentech: Stephen Miller | Principal Scientist, Early Discovery Biochemistry, Peptide Therapeutics, Drug Discovery

Scientists / Our Scientists

"It’s exciting to work with world class collaborators here at Genentech as we pursue challenging basic science questions and try to develop innovative treatments for patients in need."

Years at Genentech

Publications at Genentech

Awards & Honors

My long-term interest in peptide research started during my graduate training in the Department of Chemistry at NYU, where I developed peptide-mimetic inhibitors of protein-protein interactions and studied alpha-helical peptide folding. I then did a postdoc in the Chemical Biology Laboratory of the US National Cancer Institute to develop peptide-based biomaterials that improve drug delivery and cellular permeability. I joined Genentech at the end of 2020 and am currently a Senior Scientist in the Department of Peptide Therapeutics (Early Discovery Biochemistry). Here, my group is interested in all aspects within the discovery, development, and delivery of next generation peptide drugs.

Featured Publication

Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions.

J. Am. Chem. Soc. 2020, 142, 19950-19955.

Miller, S.E.; Tusji, K.; Abrams, R.P.M.; Burke, T.R.; Schneider, J.P.

View Abstract

My group conducts multidisciplinary research, utilizing a broad range of techniques that include protein engineering, biochemical and biophysical analyses, molecular and cell biology, medicinal chemistry, and bioconjugation. This allows us to actively participate in various stages of early discovery efforts to identify hit peptide molecules from library screening studies, validate synthetically made compounds for binding and cell activity, and optimize drug properties through re-screening efforts, structure-based rational design, and other chemical methods.

Our current research efforts are focused on the development of peptide therapeutics for tissue regeneration, inflammatory bowel disease, pulmonary fibrosis, cancer, and neurodegeneration. To push this work forward, we have ongoing collaborations with colleagues within Peptide Therapeutics and Early Discovery Biochemistry, as well as those in Immunology Discovery, Molecular Oncology, Protein Chemistry, Neuroscience, and Structural Biology.

Potent and selective binders of the E3 ubiquitin ligase ZNRF3 stimulate Wnt signaling and intestinal organoid growth

Cell Chemical Biology, ISSN: 24519456

Yvonne T. Kschonsak; Xinxin Gao; Stephen E. Miller; Sunhee Hwang; Hadir Marei; Ping Wu; Yanjie Li; Karen Ruiz; Kristel Dorighi; Loryn Holokai; Pirunthan Perampalam; Wen-Ting K. Tsai; Yee-Seir Kee; Nick Agard; Seth F. Harris; Rami N. Hannoush; Felipe de Sousa e Melo

View on Scopus

Synthetic Multivalent Disulfide-Constrained Peptide Agonists Potentiate Wnt1/β-Catenin Signaling via LRP6 Coreceptor Clustering

ACS Chemical Biology, ISSN: 15548937 15548929

Avinash K. Thakur; Stephen E. Miller; Nicholas P. D. Liau; Sunhee Hwang; Simon Hansen; Felipe de Sousa e Melo; Jawahar Sudhamsu; Rami N. Hannoush

View on Scopus

New York University, Ph.D. in Bioorganic Chemistry – 2014
New York University, M.S. in Chemistry – 2010
Syracuse University, B.S. in Chemistry – 2007

NCI-CCR Federal Technology Transfer Award – 2018
NIH Fellows Award for Research Excellence – 2018
Syracuse University Remembrance Scholar – 2006-2007

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Stephen Miller

Principal Scientist, Early Discovery Biochemistry, Peptide Therapeutics, Drug Discovery

Featured Publication

Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions.